Untargeted metabolomic analysis reveals different metabolites associated with response to mepolizumab and omalizumab in asthma.

Tanawin NopsoponYulu ChenQingwen ChenCraig E Wheelock Scott T Weiss Michael J McGeachieJessica Lasky-SuAyobami T Akenroye

Published in: ERJ open research (2024)

This study identifies distinct metabolites associated with response to mepolizumab and omalizumab, with androgenic steroids associated with response to both mepolizumab and omalizumab.

Keyphrases

ms ms
chronic obstructive pulmonary disease
mass spectrometry
genome wide
lung function
allergic rhinitis
high resolution mass spectrometry